Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.905 USD | +1.17% | +13.56% | +120.06% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+120.06% | 722M | |
+49.99% | 59.28B | |
+41.42% | 40.94B | |
-5.52% | 40.17B | |
-5.16% | 28.69B | |
+12.46% | 26.63B | |
-21.05% | 18.89B | |
+30.58% | 12.46B | |
+0.43% | 12.42B | |
+26.04% | 12.26B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Taysha Gene Therapies Secures FDA Fast Track Designation for Rett Syndrome Treatment; Shares Rise